Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureJosef Smolen, Elena Nikiphorou, Janet Pope, Loreto Carmona, Baran Ufuktepe, Immaculate Nevis, Yoshiya Tanaka, Roy M. Fleischmann
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Unresolved referenced work
Kept as external metadata until matched
Exploring the influence of baseline rheumatoid factor levels on TNF inhibitor retention rate in patients with rheumatoid arthritis: a multicentre and retrospective study
10.1136/rmdopen-2023-003975 · 2024
Rheumatoid factor and rheumatoid arthritis
10.1016/j.jcot.2019.03.007 · 2019
In early rheumatoid arthritis, anticitrullinated peptide antibodies associate with low number of affected joints and rheumatoid factor associates with systemic inflammation
10.1136/ard-2023-224728 · 2024
Influence of rheumatoid factor on serum drug levels of TNF inhibitors with different structures in rheumatoid arthritis
2024
A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis
10.1093/rheumatology/kep155 · 2009
Rheumatoid factor determines structural progression of rheumatoid arthritis dependent and independent of disease activity
10.1136/annrheumdis-2012-201517 · 2013
Rheumatoid factor isotypes in rheumatoid arthritis diagnosis and prognosis: a systematic review and meta-analysis
10.1136/rmdopen-2022-002817 · 2023
The Status of Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Antibody Are Not Associated with the Effect of Anti-TNFα Agent Treatment in Patients with Rheumatoid Arthritis: A Meta-Analysis
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
10.1371/journal.pone.0089442 · 2014
Ozoralizumab: First Approval
10.1007/s40265-022-01821-0 · 2023
Impact of high rheumatoid factor levels on treatment outcomes with certolizumab pegol and adalimumab in patients with rheumatoid arthritis
10.1093/rheumatology/keae435 · 2024
10.1186/s13075-017-1401-2
10.1186/s13075-017-1401-2 · 2017
Unresolved referenced work
2009
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
2021
Unresolved referenced work
2008
2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative
10.1136/ard.2010.138461 · 2010
Impact of dual rheumatoid factor and anti-citrullinated protein antibody seropositive, single seropositive, and seronegative rheumatoid arthritis on outcomes
10.1002/acr.80009 · 2026
Differential efficacy of TNF inhibitors with or without the immunoglobulin fragment crystallizable (Fc) portion in rheumatoid arthritis: the ANSWER cohort study
10.1007/s00296-021-05086-w · 2022
Unresolved referenced work
Kept as external metadata until matched
Assessing risk of bias in a randomized trial
10.1002/9781119536604.ch8 · 2019
Unresolved referenced work
Kept as external metadata until matched
POS0722 Purified monoclonal rheumatoid factors bind Fc containing TNF inhibitors in vitro but not the Fc-free TNF inhibitor, Certolizumab Pegol
10.1136/annrheumdis-2024-eular.2568 · 2024
Unresolved referenced work
Kept as external metadata until matched
Immunoglobulin G structure and rheumatoid factor epitopes
10.1371/journal.pone.0217624 · 2019
A novel TNF inhibitor ozoralizumab is unaffected by rheumatoid factor in the recycling mechanism via neonatal Fc receptor
2025
Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFα therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement
10.1136/ard.2003.014647 · 2004
Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment
10.1007/s00296-004-0571-9 · 2005
Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis
10.1136/ard.2004.023523 · 2005
W43-5: usefulness of certolizumab pegol useful rheumatoid arthritis with high rheumatoid factor
2024
ABS1004 Unraveling the influence of rheumatoid factor on RA treatment success
10.1016/j.ard.2025.06.1633 · 2025
Influence of rheumatoid factors on the efficacy of TNF inhibitor therapy in patients with rheumatoid arthritis
10.1007/s40744-025-00769-3 · 2025
Treatment response in patients with rheumatoid arthritis treated certolizumab pegol based on rheumatoid factor levels
2025
Do high rheumatoid factor levels impact response to certolizumab pegol in patients with inadequately controlled rheumatoid arthritis? A post hoc analysis of the phase 3b realistic trial
10.1136/annrheumdis-2024-eular.2883 · 2024
Ozoralizumab shows effectiveness regardless of baseline RF and ACPA titres in patients with RA: a post hoc analysis of the OHZORA trial
10.1093/rheumatology/keaf171 · 2025
Certolizumab inhibits radiographic progression even in RA patients with high rheumatoid factor levels: a pooled, post-hoc analysis of two phase 3 trials
2024
Efficacy of certolizumab pegol across baseline rheumatoid factor subgroups in patients with rheumatoid arthritis: post-hoc analysis of clinical trials
10.1111/1756-185x.14699 · 2023
Influence of rheumatoid factor levels and TNF inhibitor structure on secondary nonresponse in rheumatoid arthritis patients
10.3389/fmed.2024.1461396 · 2024
Fragment crystallizable (Fc)-free certolizumab pegol is not bound by rheumatoid factors, while fc containing biological DMARDsAre, driving immunecomplex formation and cellular clearance
2024
Interaction of the rheumatoid factor with antigen-antibody complexes and aggregated gamma globulin
10.1084/jem.108.1.105 · 1958
Immunogenicity of biologics in chronic inflammatory diseases: a systematic review
10.1007/s40259-017-0231-8 · 2017
Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register
10.1136/ard.2010.139774 · doi-reference
Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial
10.1016/s0140-6736(04)15640-7 · doi-reference
Certolizumab pegol does not bind the neonatal Fc receptor (FcRn): consequences for FcRn-mediated in vitro transcytosis and ex vivo human placental transfer
10.1016/j.jri.2016.04.284 · doi-reference
American College of Rheumatology/EULAR remission criteria for rheumatoid arthritis: 2022 revision
10.1136/ard-2022-223413 · doi-reference
A simplified disease activity index for rheumatoid arthritis for use in clinical practice
10.1093/rheumatology/keg072 · doi-reference
Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry
10.1136/ard-2023-225271 · doi-reference
10.1002/art.21519
10.1002/art.21519 · doi-reference